About
Hello! I report on financing, business development and other big picture trends in the…
Articles by Kyle
Activity
-
The biopharma world entered mid-May with a flurry of dealmaking and fundraising news: An Alzheimer's pact, a rare neuromuscular disease partnership…
The biopharma world entered mid-May with a flurry of dealmaking and fundraising news: An Alzheimer's pact, a rare neuromuscular disease partnership…
Shared by Kyle LaHucik
-
Gene insertion and integration is the new vanguard of the gene editing field. At #ASGCT2024 this week, David R. Liu, Tome Biosciences, SalioGen…
Gene insertion and integration is the new vanguard of the gene editing field. At #ASGCT2024 this week, David R. Liu, Tome Biosciences, SalioGen…
Liked by Kyle LaHucik
-
Maze Therapeutics quickly found a new buyer for its investigational oral treatment for Pompe disease. Five months after Sanofi backed out of a…
Maze Therapeutics quickly found a new buyer for its investigational oral treatment for Pompe disease. Five months after Sanofi backed out of a…
Shared by Kyle LaHucik
Experience
Education
Volunteer Experience
-
Eagle Scout
Boy Scouts of America
Publications
-
Personal portfolio
Kylelahucik.com is a portfolio of my personal blog, photography and projects for my journalism classes at the University of Missouri. I created this personal site in order to gain experience during my time as a Journalism and English student at MU.
Courses
-
Art Context and Culture Honors
2030H
-
Chancellor's Leadership Class: Foundations of Education
3100
-
Creative Writing: Intermediate Nonfiction Prose
2520
-
Creative Writing: Introduction to Nonfiction Prose
1520
-
Cross Cultural Journalism
2000
-
Elementary Statistics Honors
1300H
-
General Psychology
1000
-
Multimedia Journalism
2150
-
News Writing
2100
-
Principles of American Journalism
1100
-
Proseminar Interdisciplinary Studies
1001
-
Understanding Architecture and the American City
2100
-
Writing About Literature
2100
Honors & Awards
-
Andrew Family Foundation Scholarship Recipient
Andrew Family Foundation
-
Eagle Scout recipient
Boy Scouts of America
Languages
-
English
-
Organizations
-
Give A Box
Social Media Strategist, Distribution Coordinator
-
Boy Scouts of America Troop 725
Senior Patrol Leader (SPL), ASPL, Patrol Leader, Historian, Assistant Scoutmaster
More activity by Kyle
Bluejay Therapeutics disclosed a $182 million Series C on Thursday to continue developing former Novartis and Exicure treatment candidates, as well…
Bluejay Therapeutics disclosed a $182 million Series C on Thursday to continue developing former Novartis and Exicure treatment candidates, as well…
Shared by Kyle LaHucik
Novo Nordisk, maker of Wegovy and Ozempic, is doubling down on GLP-1 (while also exploring a variety of other avenues, like genetic medicines) for…
Novo Nordisk, maker of Wegovy and Ozempic, is doubling down on GLP-1 (while also exploring a variety of other avenues, like genetic medicines) for…
Shared by Kyle LaHucik
Aardvark Therapeutics targeted $50 million for its Series C but wound up raising $85 million as investors and drug developers search for what's next…
Aardvark Therapeutics targeted $50 million for its Series C but wound up raising $85 million as investors and drug developers search for what's next…
Shared by Kyle LaHucik
Beyond excited to be in Atlanta today for this year’s Health Equity Congress.
Literally planes, trains and automobiles to be here and I wouldn’t…
Beyond excited to be in Atlanta today for this year’s Health Equity Congress. Literally planes, trains and automobiles to be here and I wouldn’t…
Liked by Kyle LaHucik
Walking Fish Therapeutics was two months away from asking the FDA to clear its first clinical trial, testing whether an engineered B cell therapy…
Walking Fish Therapeutics was two months away from asking the FDA to clear its first clinical trial, testing whether an engineered B cell therapy…
Shared by Kyle LaHucik
Well, it’s been a ride. I was one of the eight reporters and editors who were laid off from The Wall Street Journal in Hong Kong and Singapore last…
Well, it’s been a ride. I was one of the eight reporters and editors who were laid off from The Wall Street Journal in Hong Kong and Singapore last…
Liked by Kyle LaHucik
⚡ Next week in New York, Endpoints News + the Financial Times are teaming up for the first time as we co-present the US #Pharma and #Biotech Summit…
⚡ Next week in New York, Endpoints News + the Financial Times are teaming up for the first time as we co-present the US #Pharma and #Biotech Summit…
Liked by Kyle LaHucik
As its AstraZeneca-partnered oral GLP-1 heads into Phase 2 testing in the second half of this year, US and China biotech Eccogene will be working on…
As its AstraZeneca-partnered oral GLP-1 heads into Phase 2 testing in the second half of this year, US and China biotech Eccogene will be working on…
Shared by Kyle LaHucik
Thanks to Kyle LaHucik at Endpoints News for highlighting the exciting things going on at Latus Bio.
https://lnkd.in/g97V_wgs
Thanks to Kyle LaHucik at Endpoints News for highlighting the exciting things going on at Latus Bio. https://lnkd.in/g97V_wgs
Liked by Kyle LaHucik
New: Radiopharmaceutical leader Novartis is buying another startup in the field as it dishes out $1 billion upfront for Mariana Oncology.
Mariana’s…
New: Radiopharmaceutical leader Novartis is buying another startup in the field as it dishes out $1 billion upfront for Mariana Oncology. Mariana’s…
Shared by Kyle LaHucik
Exclusive: Latus Bio, a CNS gene therapy biotech built on more than half a decade of work out of Spark co-founder Beverly Davidson's lab, has raised…
Exclusive: Latus Bio, a CNS gene therapy biotech built on more than half a decade of work out of Spark co-founder Beverly Davidson's lab, has raised…
Shared by Kyle LaHucik
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More